Allspring Global Investments Holdings LLC Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Allspring Global Investments Holdings LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1,080.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,313 shares of the biopharmaceutical company’s stock after acquiring an additional 16,761 shares during the period. Allspring Global Investments Holdings LLC’s holdings in TG Therapeutics were worth $326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TGTX. New York State Common Retirement Fund raised its stake in TG Therapeutics by 1.2% in the fourth quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock valued at $960,000 after buying an additional 663 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of TG Therapeutics by 22.7% in the fourth quarter. Victory Capital Management Inc. now owns 18,522 shares of the biopharmaceutical company’s stock worth $316,000 after acquiring an additional 3,424 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at approximately $233,000. Charles Schwab Investment Management Inc. raised its stake in shares of TG Therapeutics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,896 shares of the biopharmaceutical company’s stock worth $19,333,000 after acquiring an additional 19,214 shares in the last quarter. Finally, NBC Securities Inc. raised its stake in shares of TG Therapeutics by 34.5% during the fourth quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 2,409 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s shares.

Analyst upgrades and downgrades

TGTX has been the subject of a number of research analyst reports. Goldman Sachs Group boosted their price target on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research note on Tuesday, August 6th. Finally, B. Riley boosted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.83.

Get the latest stock report on TGTX

TG Therapeutics trading up 2.7%

Shares of TG Therapeutics stock opened at $22.03 on Friday. The stock has a market cap of $3.40 billion, a PE ratio of 95.78 and a beta of 2.23. The firm has a fifty day moving average price of $21.14 and a 200 day moving average price of $17.71. TG Therapeutics, Inc. has a 1 year low of $6.46 and a 1 year high of $25.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58, and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX – Get Your Free Report ) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. In the same quarter last year, the business posted ($0.34) EPS. The company’s revenue increased by 357.0% year-over-year. Equities research analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

TG Therapeutics Company Profile

(Free report)

TG Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the acquisition, development and commercialization of novel treatments for B-cell-mediated diseases in the United States and internationally. It offers BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and secondary active progressive disease in adults.

See Also

Want to see what other hedge funds own TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).

Get news and ratings for TG Therapeutics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TG Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.